Suppr超能文献

2例接受慢性腹膜透析婴儿的正常身高增长:个案报道还是与整体管理相关。

Normal statural growth in 2 infants on chronic peritoneal dialysis: anecdotal or whole management-related.

作者信息

Fischbach M, Terzic J, Menouer S, Provot E, Laugel V

机构信息

Nephrology Dialysis Transplantation Children's Unit, University Hospital, Strasbourg, France.

出版信息

Clin Nephrol. 2001 Dec;56(6):S17-20.

Abstract

AIMS

Growth retardation is usual in children on chronic peritoneal dialysis (CPD). Despite attention to many contributing factors (nutrition, dialysis dose, hemoglobin level, adynamic bone disease, hyperparathyroidism or rickets, growth hormone resistance, etc.), normal growth is rarely obtained in infants on CPD.

MATERIALS AND METHODS

We had the chance to observe normal growth over a 1 year period in 2 consecutively treated infants on CPD. Louise (renal hypodysplasia) required CPD at the age of 1 month: creatinine 430 micromol/l; oliguric, creatinine clearance lower than 5 ml/min/1.73 m2. Nutrition was achieved orally with human milk during the first 6 months of life. Tidal peritoneal dialysis allowed a high dialysis dose Kt/V urea 3.8/week and Kcreatinine 105 l/week/1.73 m2. Hemoglobin was maintained over 13 g/dl and low levels of vitamin D analogue were prescribed to avoid adynamic bone disease. At the age of 1 year her height was 75 cm. i.e. in the normal range for age. Madeline (renal hypodysplasia) commenced on CPD at the age of 6 weeks and managed similarly. Her height at 1 year of age was 74 cm.

RESULTS

In our 20 years of experience with children on dialysis, these 2 cases of normal statural growth for age at 1 year warrant discussion. As well as nutritional support, the new and recent therapeutic options in our team were: firstly, to avoid high doses of activated vitamin D to control PTH, as high doses are able to induce both a risk of adynamic bone disease and a direct bone cartilage toxicity: secondly, to maintain normal hemoglobin level; and thirdly, to deliver a high dialysis dose (urea, creatinine clearance) based on an individually adapted prescription.

CONCLUSION

We feel this management approach is necessary to achieve optimal statural growth in children on chronic peritoneal dialysis. But this management concept only based on clinical anecdotal observations needs further evaluation before its use in clinical guidelines.

摘要

目的

慢性腹膜透析(CPD)患儿生长发育迟缓很常见。尽管关注了许多促成因素(营养、透析剂量、血红蛋白水平、骨动力缺乏症、甲状旁腺功能亢进或佝偻病、生长激素抵抗等),但接受CPD治疗的婴儿很少能实现正常生长。

材料与方法

我们有幸观察了2例接受连续治疗的CPD婴儿在1年期间的正常生长情况。路易丝(肾发育不全)1个月大时开始接受CPD治疗:肌酐430微摩尔/升;少尿,肌酐清除率低于5毫升/分钟/1.73平方米。在生命的前6个月通过母乳喂养实现营养摄入。潮式腹膜透析使透析剂量较高,尿素Kt/V为3.8/周,肌酐K为105升/周/1.73平方米。血红蛋白维持在13克/分升以上,并给予低剂量的维生素D类似物以避免骨动力缺乏症。1岁时她的身高为75厘米,即处于正常年龄范围。玛德琳(肾发育不全)6周大时开始接受CPD治疗,治疗方式类似。她1岁时的身高为74厘米。

结果

在我们20年治疗透析患儿的经验中,这2例1岁时身高处于正常年龄范围的病例值得探讨。除了营养支持外,我们团队新的和最近的治疗选择包括:首先,避免使用高剂量活性维生素D来控制甲状旁腺激素,因为高剂量会导致骨动力缺乏症风险和直接的骨软骨毒性;其次,维持正常血红蛋白水平;第三,根据个体化调整的处方给予高透析剂量(尿素、肌酐清除率)。

结论

我们认为这种管理方法对于慢性腹膜透析患儿实现最佳身高增长是必要的。但这种仅基于临床轶事观察得出的管理理念在用于临床指南之前需要进一步评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验